Ampersand Capital Partners has acquired Purna Pharmaceuticals, an independent Belgian contract development and manufacturing organization (CDMO), for an undisclosed amount. This transaction marks a significant corporate acquisition, bringing Purna's specialized pharmaceutical services under Ampersand's ownership. Established in 1986, Purna Pharmaceuticals has built a strong reputation for excellence and a global presence, providing contract services for the development and manufacturing of semi-solid, powder, and liquid pharmaceutical products that meet GXP standards. The company is recognized as a preferred partner by many leading pharmaceutical multinationals, while also serving small start-ups with its agile and efficient operating model.
Beyond its core CDMO activities, Purna Pharmaceuticals actively engages in identifying innovative drugs to fulfill unmet patient needs, supporting its customers in commercial opportunities. The company invests in R&D and an innovation network, which has led to the creation of a product pipeline for out-licensing. Purna also offers a platform for scientists and owners of innovative technologies to find suitable commercial partners. Additionally, Purna exports pharmaceutical products, primarily through tender business to non-governmental organizations and national authorities, providing high-quality medicines at reasonable prices for urgent needs in underserved populations.
The acquisition by Ampersand Capital Partners, a private equity firm focused on healthcare investments, is strategically aimed at leveraging Purna's established market position, diverse service offerings, and strong customer relationships. This move is expected to support Purna's continued growth and expansion of its specialized capabilities in pharmaceutical development and manufacturing. Ampersand's investment is anticipated to enhance Purna's operational footprint and reinforce its standing as a key partner in the global pharmaceutical supply chain.
This acquisition is poised to strengthen Purna's ability to innovate and expand its reach across its various business segments, from contract manufacturing to humanitarian aid. The combined entity is expected to capitalize on Purna's expertise and Ampersand's strategic support to drive further development and deliver value to its diverse clientele and the broader pharmaceutical market.